By continuing to site, I confirm that I am a licensed healthcare professional and the intended recipient of this information, which has been provided to me directly by a Johnson & Johnson representative or authorized channel. I understand this content is not intended for public distribution and that I am familiar with the CAPLYTA pivotal trial data.

I further acknowledge there have been no head-to-head clinical trials comparing the Johnson & Johnson product approved for the adjunctive treatment of adults with major depressive disorder with any other agent.

Image of savings cardSavings
CardLocal
Coverage
 FinderSamples

References: 1. Cutler AJ, Lemyre A, Zhang Q, et al. Efficacy and safety of lumateperone and other atypical antipsychotics approved as adjunctive treatment for major depressive disorder in the United States: a network meta-analysis. Adv Ther. Published online June 12, 2026. https://doi.org/10.1007/s12325-026-03630-3 2. Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). 2017;15(1):943. doi:10.18549/PharmPract.2017.01.943 3. Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103-111. doi:10.1007/s11739-016-1583-7 4. CAPLYTA [Prescribing Information]. Titusville, NJ: Intra-Cellular Therapies, Inc. 5. Durgam S, Earley WR, Kozauer SG, et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry. 2025;86(4):25m15848. doi:10.4088/JCP.25m15848 6. Durgam S, Earley WR, Kozauer SG, et al. Adjunctive lumateperone in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. Am J Psychiatry. 2025;182(12):1072-1082. doi:10.1176/appi.ajp.20250292 7. Data on file. Intra-Cellular Therapies, Inc. 8. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Effect sizes based on means. In: Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, eds. Introduction to Meta-Analysis. John Wiley & Sons; 2009:21-32. 9. Katz KA. The (relative) risks of using odds ratios. Arch Dermatol. 2006;142(6):761-764. doi:10.1001/archderm.142.6.761 10. Hespanhol L, Vallio CS, Costa LM, Saragiotto BT. Understanding and interpreting confidence and credible intervals around effect estimates. Braz J Phys Ther. 2019;23(4):290-301. doi:10.1016/j.bjpt.2018.12.006 11. Ruscio J, Mullen T. Confidence intervals for the probability of superiority effect size measure and the area under a receiver operating characteristic curve. Multivariate Behav Res. 2012;47(2):201-223. doi:10.1080/00273171.2012.658329 12. Cutler AJ, Lemyre A, Zhang Q, et al. Efficacy and safety of lumateperone and other atypical antipsychotics approved as adjunctive treatment for major depressive disorder in the United States: a network meta-analysis. Adv Ther. Published online June 12, 2026;(suppl). https://doi.org/10.1007/s12325-026-03630-3 13. Earley WR, Durgam S, Kozauer SG, Chen C, Migliore R, Correll CU. Safety and tolerability of adjunctive lumateperone for the treatment of major depressive disorder: a pooled analysis of two randomized placebo-controlled trials. CNS Drugs. Published online 2026. doi:10.1007/s40263-026-01314-8

Loading Global Footer...